Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells 3,651 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 3,651 shares of the business’s stock in a transaction dated Wednesday, January 14th. The stock was sold at an average price of $40.53, for a total value of $147,975.03. Following the completion of the transaction, the chief executive officer directly owned 47,457 shares of the company’s stock, valued at approximately $1,923,432.21. This trade represents a 7.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.02, for a total transaction of $117,338.64.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.16, for a total transaction of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total transaction of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total transaction of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total transaction of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.06, for a total value of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.77, for a total value of $143,510.40.
• On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $43.93, for a total value of $309,267.20.
• On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.02, for a total value of $232,425.60.

Phibro Animal Health Stock Performance

NASDAQ:PAHC traded up $0.19 on Thursday, hitting $40.06. The stock had a trading volume of 176,958 shares, compared to its average volume of 194,706. The business’s 50-day simple moving average is $40.70 and its two-hundred day simple moving average is $36.90. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of 24.13, a price-to-earnings-growth ratio of 1.14 and a beta of 0.79. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $46.42. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.15. The firm had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, research analysts predict that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were paid a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. The ex-dividend date was Wednesday, November 26th. Phibro Animal Health’s dividend payout ratio (DPR) is currently 28.92%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PAHC. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $31.40.

Institutional Investors Weigh In On Phibro Animal Health

Several institutional investors have recently made changes to their positions in the company. Financial Management Professionals Inc. purchased a new position in shares of Phibro Animal Health during the 2nd quarter worth about $32,000. Hughes Financial Services LLC purchased a new stake in Phibro Animal Health in the 3rd quarter worth about $40,000. iSAM Funds UK Ltd purchased a new stake in Phibro Animal Health in the 3rd quarter worth about $61,000. EverSource Wealth Advisors LLC lifted its stake in Phibro Animal Health by 7,671.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after purchasing an additional 2,685 shares during the last quarter. Finally, Advisory Services Network LLC purchased a new position in shares of Phibro Animal Health during the third quarter valued at approximately $96,000. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.